header logo image


Page 827«..1020..826827828829..840850..»

Is Genetic Testing Worth the Time? – Curetoday.com

November 5th, 2019 2:48 pm

Before undergoing genetic testing, stop to consider its effect on your daily experience, including your ability to get life insurance.

A few months later, my moms cancer came back. It had metastasized to her brain and eventually found a home in her bones, liver and lungs. Shortly before her death in late 2005, while we were eating lunch, my mom mentioned that she wished shed gotten more life insurance. This emotional math equation struck me as genuinely morbid. How can you attach a dollar amount to a life missed, time not spent together? What is the cost of a broken heart?

Months after my mother died, a check arrived in the mail. Now, almost 14 years later, the money is long gone. I spent it hosting holidays, on a birthday gift to myself every year for almost a decade, on gifts for my two children when they were born and on the medical bills from breast cancer screenings that my health insurance didnt cover. The last chunk went to the deductible for my preventive mastectomy in 2013. I appreciated every penny and didnt take for granted that I had a decade-long cushion allowing me to do things that would have otherwise been outside my reach. My mothers life insurance money allowed me to take the steps to secure my healthy future.

In 2008, I finally had genetic testing and learned that I didnt have the BRCA mutation. But because of other hereditary risk factors, including a family history of breast cancer, I started regular screening until I decided to pursue surgical intervention.

Over the last year, my preventive oncologist has been suggesting that I undergo expanded panel testing. In the years since my initial testing, many more genetic markers for breast cancer have been discovered. The thought of having more testing sent me into a tailspin at first. My anxious and uneasy feelings recalled the hurricane of emotions I felt when my mom died, when a routine ultrasound revealed I had a breast lump and when I faced a series of emotional choices about surgery and reconstruction. What would I do if I learned I had a mutation that predisposed me to other cancers? Would I need more surgery? What additional foreshadowing would this have for my childrens health? I simply wasnt ready to know.

Even in what can be considered a best-case scenario, in which I was able to make the choice to reduce my cancer risk through surgery, this decision required me to put my whole life on pause. I juggled the logistics of single parenthood, surgery, my job and household management pretty well, though Id be remiss to ignore the army of help I had. However, my life was still affected by many critical things that none of my doctors ever discussed.

The list of things I was unprepared for due to my preventive mastectomy is almost endless. Here are a few examples:

Not a single person suggested that I get life insurance before undergoing genetic testing, nor did it occur to me to consider how it would affect my (and my childrens) ability to get insured until I met a previvor who sells insurance, which brought the topic to the front of my mind. Now, I feel lucky that Ive been putting off a second round of testing, because the delay gives me time to explore our life insurance options.

This process, and the time Im taking to do it, has given me perspective on my experience with screening, mastectomy and reconstruction. In hindsight, I realize that I should have taken more time to ask my doctor questions and brought a friend to take notes. I should have talked with more women about their experience to help guide my choices and better inform me about my options. Now, when I meet women facing these choices, that is the advice I give.

Of course, this lesson about slowing down and being more considerate is one I can use in all areas of my life.

As a breast cancer previvor, Kristen Carbone recognizes the need to feel vital and strong in both mind and body after mastectomy. In 2016, she founded Brilliantly (brilliantly.co), a brand that provides full-spectrum solutions and support to women so they can prosper and reclaim themselves along their journey.

More here:
Is Genetic Testing Worth the Time? - Curetoday.com

Read More...

Healthcast: The importance of genetic testing – KLBK | KAMC | EverythingLubbock.com

November 5th, 2019 2:48 pm

LUBBOCK, Texas Family trees show where youve been.

But the family tree that genetic counselor Julie Beasley shows her patients at Joe Arrington Cancer Center shows what their future could look like.

Genetics is important for everybody no matter your gender, your race, your age, explained Beasley. Genetic testing and family history can play a vital role in healthcare for any role in any race.

She talks to people who have cancer or family history of cancer and helps them figure out if something is hereditary or can expose them to cancer in their family.

Its important to know your family history to get an idea of whats in your family but not just what they were diagnosed with but how old were they or was it a rare type of cancer, Beasley explained.

This testing can help patients get diagnosed earlier or could prevent it all together.

Interpreters are also available for people who dont speak English so they can also understand what is going on.

I think its very important because sometimes theyre scared to come in because of the diagnosis but if they dont completely understand whats going on then they may not be willing to come back, said Delia Rubio, intake coordinator at Covenant Health. This way theyre informed and they know.

Beasley hopes patients will see the importance of genetic testing and how it can benefit people in the future.

If patients know its there we can help them with managing it so they dont worry as much and they can put that behind them, said Beasley.

Go here to see the original:
Healthcast: The importance of genetic testing - KLBK | KAMC | EverythingLubbock.com

Read More...

GPs urged to inform women about pre-pregnancy genetic testing – The Age

November 5th, 2019 2:48 pm

This is concerning, the study's lead researcher Dr Ruth Leibowitz said, because GPs are the first point of call for most pregnant women and those seeking preconception medical care.

Loading

"One theory is that GPs simply dont really know about the tests and the majority of these tests are being driven by patients requesting it," Dr Leibowitz said during a presentation of her findings at the GP19 conference in Adelaide last Friday.

When prenatal testing shows a fetus is at risk, families are faced with a profound and difficult decision on whether to keep the baby or terminate the pregnancy.

Many couples who are found to be carriers of the mutations prior to pregnancy can use IVF in conjunction with genetic testing of embryos to avoid having a child with a genetic condition.

Of the 21,172 women screened, one in 20 were carriers for at least one of the severe genetic disorders.

About 70 per cent were in the highest socio-economic quartile as measured by residential postcode. About 53 per cent were pregnant at the time of screening.

Earlier this year, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists set new guidelines, recommending that all women planning a pregnancy or in their first trimester should be given information about preconception carrier screening.

But Professor Martin Delatycki, clinical director of the Victorian Clinical Genetics Services and member of the Genomics Advisory Working Group, estimates less than 10 per cent of aspiring parents are offered such screening.

Loading

"What the results show us is that GPs are in an ideal position to offer it because they see women before they are pregnant," Professor Delatycki said.

"When women are not pregnant and they have screening, they have much more time to make a decision if theyre at high risk of having a child with one of the genetic conditions.

"It is very critical its a choice for people, not just a routine test," he said. "Because its not right for everybody.

Royal Australian College of General Practitioners president Harry Nespolon argued the onus should be on obstetricians with the expertise to discuss genetic testing with would-be parents, with many GPs choosing to refer women on to genetic counsellors.

For some patients, testing for the rare conditions went against their belief system, Dr Nespolon said.

"This is not a decision to be taken lightly because there is a lot to consider about requesting genetic screening, ultimately it can affect patients pyschologically and financially. It can affect people quite deeply and the choices they make."

Carrier screening to determine if couples carry the mutations for SMA, cystic fibrosis and fragile X is not routinely offered and many doctors do not know the tests exist.

Loading

Professor Delatycki said recent research pointed to women having a higher chance of having a baby with one of the three genetic conditions, than there is of having a baby with Down Syndrome.

The tests can cost up to $1800 for couples and are not covered by Medicare, prompting concerns that only wealthy aspiring parents can take this precaution in a bid to avoid having a baby with a severe genetic condition.

Fragile X syndrome causes intellectual disability and behavioural and learning challenges, and is also the most common single-gene cause of autism worldwide. Spinal muscular atrophy is a severe muscle-wasting disease, while cystic fibrosis damages the lungs and digestive system.

The landmark Mackenzie's Mission trial has begun recruiting 10,000 Australian couples to be screened for 500 severe and deadly genetic conditions.

The results of the trial are expected to inform whether the federal government will introduce Medicare subsidies for carrier screening.

Melissa Cunningham is The Age's health reporter.

Follow this link:
GPs urged to inform women about pre-pregnancy genetic testing - The Age

Read More...

Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate – Business Wire

November 5th, 2019 2:48 pm

BOTHELL, Wash. & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license agreement for an advanced preclinical product candidate for treating cancer. The agent utilizes a proprietary Seattle Genetics antibody-based technology and is expected to advance into clinical trials in the first half of 2020.

Under the terms of the agreement, Seattle Genetics has retained rights to the product candidate in the Americas (United States, Canada and Latin American countries), Europe and Japan. BeiGene has been granted exclusive rights to develop and commercialize the product candidate in Asia (except Japan) and the rest of the world. Seattle Genetics will lead global development and BeiGene will fund and operationalize the portion of global clinical trials attributable to its territories. BeiGene will also be responsible for all clinical development and regulatory submissions specific to its territories. Seattle Genetics will receive an upfront payment and is eligible to receive progress-dependent milestones for a total deal value of up to $160 million and tiered royalties on any product sales.

Collaborating with BeiGene on this product candidate has the potential to accelerate its availability both globally and in several key geographic regions, notably China where there is an unmet medical need for anti-cancer therapies, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. BeiGene brings to this collaboration strong clinical and commercial capabilities and a focus on innovative, targeted oncology drugs. We look forward to working together to develop this therapy for patients worldwide.

Seattle Genetics is recognized for its transformative oncology discoveries and we are excited to collaborate on the global development of this new drug candidate. This collaboration ties closely to our mission, to bring meaningful and innovative new medicines to patients around the world, through our commitment to world-class clinical development and commercialization, said Lai Wang, Ph.D., Senior Vice President, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development at BeiGene. The pending start of this new global trial adds a complementary molecule to our broad oncology development program, which now includes more than 60 clinical trials around the world.

About Seattle Genetics

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has a late-stage pipeline including enfortumab vedotin for metastatic urothelial cancer, currently being reviewed for approval by the FDA, and tisotumab vedotin in clinical trials for metastatic cervical cancer, which utilize our proprietary ADC technology. In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. We are also leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. The company is headquartered in Bothell, Washington, and has a European office in Switzerland. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,000 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE (nanoparticle albuminbound paclitaxel), REVLIMID (lenalidomide), and VIDAZA (azacitidine) in China under a license from Celgene Corporation.i

Seattle Genetics Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the development and commercialization of the specified product candidate and the possible financial payments from BeiGene to Seattle Genetics. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks associated with developing and commercializing novel drug candidates and that the collaboration agreement may be modified, terminated, or not provide anticipated benefits. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

BeiGene Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding future development and potential commercialization activities of the specified product candidate under the agreement with Seattle Genetics, potential payments payable to Seattle Genetics, the speed and outcome of drug development plans, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

i ABRAXANE, REVLIMID and VIDAZA are registered trademarks of Celgene Corporation.

Read the original here:
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate - Business Wire

Read More...

Science news in brief: From lab-grown steak to the world’s loudest birdsong – The Independent

November 5th, 2019 2:47 pm

Lab-grown steak gets a little muscle

The alt-meat industry has created quite a sizzle, promising delicious burgers, steaks and even sushi that is grown from animal cells in the lab.

But most cellular agriculture still looks like mush. The manufacturing process which starts with animal muscle and fat grown from stem cells in petri dishes is fine for making burgers, but it fails to provide the kind of texture needed for more substantial cuts of meat, like steaks.

Sharing the full story, not just the headlines

But scientists at Harvard University are reporting in a new study that they have found how to more closely mimic the form and flavour of real meat, by growing the muscle cells of cows and rabbits on a gelatine scaffold. Their research was published in the journal Science of Food.

To mimic this cellular environment, Kevin Kit Parker, a bioengineer at Harvard, and his colleagues decided to make scaffolds out of different concentrations of gelatine, a protein product derived from collagen. When collagen-rich meat cuts, such as beef chuck, are cooked, the heat naturally melts collagen fibres into softer gelatine, giving meat its succulent texture, Parker says.

To make gelatine microfibres, the researchers dissolved commercially available gelatine powder in water and spun it like cotton candy. Rotating the gelatinous slurry at high speeds allowed fibres to form at the bottom of the spinner. Using enzymes, the researchers then cross-linked the fibres to form a strong, woven structure for cells to grow on.

Rabbit and cow cells latched onto the gelatine scaffold, growing until they formed about a square inch of muscle.

To test whether the final product resembled the texture and behaviour of meat that chefs and home cooks use every day, the researchers performed a variety of food industry analyses: simulating cooking by heating the lab-grown meat on a hot plate, compressing it as if with a meat mallet and measuring the force needed to cut each piece of meat. They found that their lab-grown meat fell in between the springiness of a hamburger and a beef tenderloin.

Katsura leaves have a brown sugar scent (Getty/iStock)

Ahautumn, time to sniff that pumpkin spice and katsura?

Sugar, red and Japanese maples: you can drive up and down the East Coast of the US to enjoy their fiery pyrotechnic shows each fall. Along the way, you may want to stop, take a deep breath and try to catch a whiff of the katsura trees sweet scent.

Autumn seems to belong to pumpkin spice, and odours are often overlooked when it comes to fall foliage. We rave about how leaves die colourful deaths and rarely discuss how their scent changes with old age. But right about now, the leaves of the katsura, found all over New York City and in many other parts of the United States, are just beginning to turn.

Autumns earthy scent is the work of fungi and bacteria that decompose plant matter in the soil. But a chemical reaction in katsura leaves conjures fall spice, caramel and burntsugar. As the leaves ignite, changing from plum purple or green to yellow, they abandon the hay-like smell of leftover chlorophyll and adopt a scent more appropriate for a bakery.

Only the best news in your inbox

A team led by Ralf Berger, a flavour researcher in Germany, collected and analysed leaves from katsura trees throughout the year, and found maltol, a chemical compound used in flavour enhancers, perfume and incense.

Scientists have discovered crabs have a better memory than previously thought (Swansea University)

Its right turns only for some crabs in laboratory maze

Shore crabs can learn to navigate a lab-rat-style maze and remember it weeks later, according to a new study. While crabs that have never seen the maze before bump around aimlessly, experienced crabs race to the finish line with no wrong turns. The study, one of the few to look at whether crustaceans can perform such feats, suggests that crabs are quite capable of remembering routes.

Maze running could also be a way to measure the effects of changes in the sea, such as ocean acidification and warming, on crabs cognitive abilities.

The draw of nectar helped butterflies evolve (Getty)

How the butterfly discovered daylight

Once upon a time, perhaps some 300 million years ago, a tiny stream-dwelling insect akin to a caddis fly crawled from the water and began to live on mosses and other land plants. The creature would become the ancestor of the 160,000 species of moths and butterflies that populate Earth today.

A new study explains why nocturnal moths evolved into daytime butterflies. It wasnt to avoid darkness-loving bats, as biologists once thought, but to enjoy an abundant new drink: the nectar of flowering plants.

The researchers reconstructed the ancient timeline using DNA sequences of contemporary moths and butterflies. They calculated that the ancestral moth emerged some 300 million years ago, at the end of the Carboniferous era, well before the oldest known moth fossil, which is only 200 million years old.

The bellbirds song rivals the loudness of a pile driver (AFP/Getty)

He sings very loudly, just not very well

The pressures of sexual selection have made peacocks gorgeous, wood thrushes sonorous and birds of paradise great dancers. The white bellbird has a different quality.

This goofball boasts the loudest birdsong ever recorded, according to a new paper. And he sings the most piercing note right into potential mates faces.

The white bellbird is a favourite among birders in Brazil. When several sing at once, they are deafening, and sound like several blacksmiths trying to compete, says Arthur Gomes, a student who contributed to the research. Until a few years ago, assessing the amplitude, or loudness, of birdsong required an unusual amount of devotion and tech-savvy. But new tools are making the pursuit much easier.

New York Times

Go here to see the original:
Science news in brief: From lab-grown steak to the world's loudest birdsong - The Independent

Read More...

VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen – PR Web

November 5th, 2019 2:47 pm

His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

POWAY, Calif. (PRWEB) November 05, 2019

Ole, a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. He was lame and stiff and had difficulty with stairs and jumping. Though his energy level and his willingness to play were normal, it was clear that he was in pain.

Oles owner took him to veterinary surgeon Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center in San Diego, California. Dr. Mullen is an experienced VetStem user and has provided VetStem Cell Therapy services for over sixty patients. Upon examination, Dr. Mullen diagnosed Ole with severe osteoarthritis in his hips as a result of hip dysplasia. In patients with joint dysplasia, the affected joint is malformed causing the bone to rub irregularly, which can eventually lead to osteoarthritis. Ole was also diagnosed with osteoarthritis in his lower, or lumbar, spine. It was apparent that these issues were causing Ole discomfort.

In an effort to provide relief, Dr. Mullen recommended Ole receive VetStem Cell Therapy. Adipose-, or fat-derived, stem cell therapy is used by veterinarians to treat osteoarthritis and soft tissue injuries. VetStem Cell Therapy utilizes a patients natural healing cells which may reduce inflammation, block pain, and regenerate damaged joint tissues.

To begin the process, Dr. Mullen extracted fat from Oles abdomen in a minimally invasive anesthetic procedure. The fat was delivered to the VetStem laboratory in Poway, California where it was received and aseptically processed by trained VetStem laboratory technicians. Oles stem cells were extracted and concentrated from his fat tissue and dosed out into an injection that was delivered back to Dr. Mullen. Within 48 hours of the initial fat collection, Ole received one intravenous injection of his own stem cells.

As a follow up to his first injection, Ole received additional stem cell injections approximately two months later. This time he received one injection into each hip, injections along the muscles in his back, as well as an intravenous injection.

In a 90-day post stem cell therapy evaluation (approximately 90 days after the first treatment), Oles owner reported that he was no longer stiff or painful. She also noticed an improvement in his ability to go up and down the stairs, walk, and jump. His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

Dr. Mullens findings were similar at the 90-day examination. She stated, He is doing great! He runs around [the owners] acreage every day with no overt lameness and no signs of painhes strongly ambulatory with a bouncy gait.

Like Ole, many dogs suffer from osteoarthritis and unfortunately, treatment options are somewhat limited. For these patients, VetStem Cell Therapy may be an option. According to owners and veterinarians, greater than 80% of dogs showed an improved quality of life after receiving VetStem Cell Therapy for orthopedic conditions. Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. In a peer-reviewed study of dogs with chronic osteoarthritis of the hip, it was found that stem cells reduced lameness and pain.

About Holly Mullen, DVM, DACVSDr. Mullen received her DVM from Virginia-Maryland Regional College of Veterinary Medicine in 1985. She completed a small animal medicine and surgery internship as well as a residency in small animal surgery at the Animal Medical Center in New York City. In 1990, she became a board-certified veterinary surgeon. Dr. Mullen has been providing VetStem Cell Therapy for over a decade.

About VetStem Biopharma, Inc.VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Share article on social media or email:

Continue reading here:
VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web

Read More...

How Stem Cells Can Heal The Body – Version Weekly

November 5th, 2019 2:47 pm

Stem cells from the patients body when isolated and administered at an appropriate time and at the right place, with the right dose, is expected to help the patient in various ways

Stem Cells In The Body

All humans are born and develop from a small tiny structure called an egg. The cells in the egg have a tremendous potential to develop, multiply and form different cells that are functional in the body. These cells are called mother cells or in scientific terms, they are called stem cells. And all human beings have these stem cells preserved in the body. It is these cells that help us in every day wear and tear and also for tissue repair.

The Body Can Heal Itself

Most of the cells in our body have a definite lifespan that need to be replaced by new cells. The stem cell reserves in the body make up for this and it is done without our knowledge! In fact, any cut or injury, external or internal is healed by the bodys innate mechanism. Our intelligent body recognises the signal of injury and recruits the required stem cells. These stem cells transform themselves into the cells that are required for the repair of the injury and it is always many types of cells in various permutations and combinations.

Where Stem Cells Reside

Bone marrow can be considered as the manufacturing unit of stem cells as it is continuously making blood cells and keeps our circulatory system working perfect all the time. Circulating blood is another source of stem cells, because it works as a courier, carrying cells and other essential enzymes, hormones from one organ to the other in the body. The body converts all the extra material into fat which gets accumulated around the belly. This fatty tissue works like a fixed deposit of stem cells.

Stem cells either from the donor (allogenic) or from the patient (autologous) are being used for more than 50 years and especially for treatment. Blood cancers and other blood-related diseases can be cured using a perfect matched donor stem cells obtained from bone marrow. Patients suffering from organ cancers like breast cancer etc. are given autologous stem cells as a supportive treatment along with chemotherapy and/or radiation.

Protocols for these treatments are standardised globally and considered as standard-of-care. In recent years, umbilical cord blood derived stem cells are being used as an alternative to bone marrow, especially in the paediatric age group. People fall victim to numerous degenerative diseases which occur, as the repairing stem cell system from the body fails slowly with age. Stem cells from the patients body when isolated and administered at an appropriate time and at the right place, with the right dose, is expected to help the patient in various ways. It may also replace, rejuvenate or restore the damaged tissues.

Our body carnes its own repairing kit in the form of stem cells and the body tries its level best to make use of these stem cells to ward off diseases. However, it is possible that with age, the bodys power to recruit and make use of the stem cells diminishes slowly. This is when dreadful degenerative diseases like diabetes, arthritis, Parkinsons disease and heart problems, set in. Heres what the clinical applications of regenerative medicine have found novel mechanisms of:

It is increasingly observed that this kind of autologous therapy takes care of the root cause of disease and offers benefits to patients to whom there is no further solution in other modalities of treatment.

Since each tissue and organ of our body is made up of cells that are derived from the egg cell, any disease which is due to derangement or degeneration of cells can be cured using autologous cellular therapy. And though the list can be endless, here are some examples where there have been very promising results:

Follow this link:
How Stem Cells Can Heal The Body - Version Weekly

Read More...

UM Today the Magazine | Fall 2019 | After the Fire – UM Today

November 5th, 2019 2:47 pm

Twenty seconds. Give or take.

Spencer Beach cant say for sure just how long he was on fire.

Long enough to stumble to two exitstwiceand yank on door handles that wouldnt budge.

The flash fire that engulfed him in an Edmonton home was sucking in all the oxygen, creating a vacuum that sealed him inside. A flooring installer by trade, he had been removing linoleum in the laundry rooma rush job since the manufacturer mislabelled the boxes and the contractor didnt want to incur penalties for a delay. Beach and the rest of the crew were often told to use their boss homemade shortcut: douse the flooring in a contact thinner to reactivate the glue. That way, you could just peel it off.

He was on his hands and knees when he first heard a whistle as loud as a thousand kettles, followed by a boom as the furnace set the fumes alight.

Now the skin on his face felt like it was shrinking. His lips, like theyd been swarmed by bees.

The heat was inside of me. It wasnt like any burn youve ever felt, Beach says. It was everywhere.

With no way out, he curled up on the floor, interlocking his fingers behind his head. His mind flashed to his wife, Tina, blonde and four months pregnant with their first child. He had just left her a voice message: the job was nearly done, he was the only one left, hed be home soon. Tonight, hed plan his buddys stag party.

Beach got to his feet and tried the door one more time.

In his right hand, Dr. Sarvesh Logsetty holds a pair of scissors. In his left, a piece of paper grabbed from the many stacks in his office at Winnipegs Health Sciences Centre (HSC), where he is head of the burn unit.

The surgeon is stumped.

Hes trying to remember the strategic cuts to make for a trick he would do as a kid. Its a paper craft that turns a 4-by-5-inch sheet into an open shape large enough to walk through.

What am I doing wrong?

Logsetty wants to use the analogy to explain the skin graft meshing techniques he routinely does for patients whove suffered severe burns to large swaths of their body. The techniques also use strategic cutsto expand pieces of skin up to nine times their original size.

Every centimetre counts in these life-saving reconstructive surgeries where patches of unharmed skin are removed from one site to cover another, explains the University of Manitoba professor of surgery and psychiatry.

Ta da, he says, holding up the large paper circle. Damn, that was driving me insane.

Dr. Sarvesh Logsetty's curiosity about suturing goes back to age four, to Hyderabad, India, where he would hang around the medical clinic run by his great-aunt // PHOTO BY DAVID LIPNOWSKI [BA(HONS)/08]

Finding solutions is what the 51-year-old has spent decades doing, to alleviate pain and hardship for burn patients. Each one of my research projects, he says, reflects a patients journey.

Logsetty knows Beachs well, having operated on him more than a dozen times. He was working the day Beach was rushed to University of Alberta Hospital. The surgeon remembers how this 29-year-oldwith burns to more than 90 per cent of his bodywas more worried about how others would handle the news than he was his own chances for survival (about five per cent).

Even afterwards, hes always thought about how he can help other people and how he can use his experience to help them get through, says Logsetty, who brought his expertise to UM in 2007.

One persons recovery involves a slew of professionals.

Beyond nurses to do dressing changes, there are dietitians, physiotherapists, occupational therapists, psychologists, psychiatrists and social workers. On the burn ward at HSC, the team includes UM students across disciplines. The unit admits 100 to 200 patients a year, and treats another 250 to 400 (including cases of frostbite and flesh-eating disease). About 40 per cent of patients are children. Among the adults, the majority are men, who tend to engage in riskier behaviour than women, Logsetty notes.

When compared to other health conditions, theres an added layer. With any burn, theres a sense of guilt. Did I do something that caused this? Especially as a parent. That adds to the burden, says Logsetty. Its different than something spontaneous like cancer, where it isnt that they left the oil on the stove for too long or didnt check the temperature when they put their child in the bathtub.

With any burn, theres a sense of guilt. Did I do something that caused this? Especially as a parent. That adds to the burden. SARVESH LOGSETTY

Among 20- to 60-year-olds, burns are most often flame-related mishaps involving cooking oils catching fire, accelerants flashing back while burning grass, or house fires erupting in the night, Logsetty says. Burns from scalding are most common in kids and the elderly.

His research probes what social determinants increase your chances. A study released with UM psychiatrist Dr. Jitender Sareen [MD/95, BSc(Med)/95] last year showed people with a low income were as much as five times more likely to suffer burns. And the researchers mapped high-incidence areas in Winnipeg for policymakers to target prevention strategies.

Logsetty offers a window into the daily challenges on the burn unit. Within its dual-chamber isolation rooms, theres an ongoing battle against infection, down to the microscopic fibres of hospital curtains that may harbour antibiotic-resistant bacteria.

Burn patients face a far greater risk because their injuries arent straightforward open wounds. Theres dead skin sitting there, providing a perfect food source for bacteria. And because the skin is dead, theres no link to the bodys blood. No trigger to get infection-fighting white blood cells to activate and defend. So the bacteria can happily grow, getting stronger, says Logsetty. The risk of infection is really high.

The seeping wounds are kept covered and clean. Peeling off the dressings can be excruciatingly painful and take hours. No matter what we use, the dressings tend to stick, says Logsetty. This agony is what drives him and UM collaborator Song Liu, a medical microbiology and infectious diseases researcher, also in the Rady Faculty of Health Sciences, in their efforts to reinvent the burn bandage.

Together, theyre developing not only a less sticky coating but a dressing they hope will transform burn care. Theyre designing a fabric to detect infection, alert medical staff by changing colour, and then release antibiotics from withinall without having to remove it, Logsetty says.

Different colours would indicate different bugs. If the spot of colour were to grow bigger, it would tell nurses the infection wasnt getting any better. The bandage will be made of nanofibres, or straw-like chemical structures that break down when they come into contact with bacterial enzymes. The centres will be filled with either a liquid to release dye or a liquid containing the antibiotic. A bandage that both diagnoses and treats infection would be a first in the field. Logsetty says they could have a tangible product in as little as five years.

Liu also holds a patent for an antibiotic-resistant fabric, which could one day mean self-cleaning hospital curtains. He bonded a chlorine-like chemical to the curtain that kills bacteria on contact, one that not only wont wash out in the laundry but is reactivated by water. One of Logsettys recent studies showed that, within two weeks of being washed, five out of eight untreated hospital curtains tested positive for antibiotic-resistant MRSA.

PHOTOS BY AMBER BRACKEN

Leather hiking boots. Leather knee pads. A leather work belt. Beach didnt think twice about the gear he put on the morning of Aug. 24, 2003. (But he did contemplate calling in sickjust a feeling that he should, but one he ignored.)

The leather is what saved the less than 10 per cent of Beachs body surface that wasnt burned. His feet below the ankles. A patch in the middle of each knee. His waistline.

Theres a line around my waist where you could see where my belt was, he says.

Only once the vapours and air pressure subsided in the home was he able to open the door to the garage and escape. A neighbour then came running with a hose.

Since that day, Beach has undergone 38 surgeries.

His burns reveal the most severe form: third- and fourth-degree, which tear through the epidermis and dermis and extend into the muscle, fat and bones. At first, these sites (that appear white or charred-black) are the least painful for patients, since the flames have destroyed the nerve endings.

While lesser burns can heal on their ownas cells lining our sweat ducts and hair follicles automatically spread out to rebuildsevere burns require grafting.

Skin from Beachs feet is now on his face. As is skin from his knees and hip. Pieces of his foreskin form his delicate, upper eyelids while skin from his scrotum shapes his lower.

Logsetty can use meshing instruments that stretch and expand what small percentage of skin survivesthe graphs look like criss-crossed grids, almost translucentbut each time he does, the skin gets thinner, leaving more room for scar tissue to fill in the gaps. Its the scarring that leads to chronic pain.

[With Beach] I had to take three per cent and expand it into more than 90 per cent, somehow or another, says Logsetty. The key to advancing burn care, he says, is to develop ways to grow better skin.

[With Beach] I had to take three per cent and expand it into more than 90 per cent, somehow or another. SARVESH LOGSETTY

Beach received synthetic skin, as well as skin from cadavers, before new skin was cultured from his own cells. With Logsetty at the helm, Beach became the firstand is still the onlyCanadian to receive a unique, double-layer skin thats more resilient than anything thats come before. A sample of his skin, the size of a business card, was cultured in a lab in Cincinnati, OH, and then multiplied time and time again to eventually cover nearly half his body.

Experimental in the early 2000s, the technique is still innovative today, says Logsetty, but not yet widely available because the company has faced hurdles bringing it to market. From an overall standards of burn care, its a gamechanger, he says.

Even though there are still improvements to makethe skin doesnt contain pigment, hair follicles or sweat ducts (so on a hot summer day, Beach has to watch for heat stroke)it means less scarring and greater quality of life, says Logsetty.

Hes also in the process of developing a research project at UM that will explore new ways to use stem cells to create skin, and is collaborating with a Quebec company, Loex, on a similarly robust skin alternative.

Skin-grafting surgeries can be marathons of endurance and difficulty. An intensive operation can take 12 hours, but shorter is best since patients are already so unstable going in. The temperature of the room is kept at 29.9C to prevent patients from becoming hypothermic. Their whole body is exposed on the tablein order to graft different areasand without skin, theyre without a key organ that helps regulate body temperature. When our temperature drops, we bleed more, so theres also a greater risk of bleeding out on the table. Disposable warming blankets, inflated with warm air, help retain heat.

In the stifling environment, Logsetty and the team wear surgical gowns made of Gortex or other waterproof fabrics. (One of his research projects studies the effects on the medical team, including how much weight they lose from sweat during a procedure.)

On this ward, named after Manitoba firefighters, the mortality rate is less than three per cent, on par with the top burn centres across North America, notes Logsetty. Not many of their patients are firefighters nowadays, given how safety training and gear have evolved. But unfortunately, when they do become injured, he says, its usually devastating.

Nine months after the fire, Beach rolled over for the first time. He had lost 63 pounds and at six-foot-two was down to 112. The scar tissue had built up on his ligaments and tendons, and his muscles were wasting away with atrophy. The movement was small but it felt like a big win that came just in time. After the fire, he was angry, depressed, suicidal; now he wanted to see what else he could do for himself.

With progress comes greater survival rates, which mean more people living with the long-term consequences of burn injuries like disability, financial problems and chronic pain. Trauma survivors are at least four times more likely to take their own life, Logsetty and Sareen revealed in a 2014 study. Theyve since discovered theyre also twice as likely to have depression, anxiety or substance-abuse issues.

The standard of care I try to hold myself toand teach my studentsis What would you expect for you or your loved one? SARVESH LOGSETTY

Logsetty says patients often tell him they dont want to go on. He helps them reintegrate with the life they once had, as much as possible. Its not, I fixed your hernia, your sutures are out, you can call me if you have a problem. There is a continuity of care we dont see in most other surgery.

Thats why hes made this his lifes work. One patient describes Logsetty as the most caring and considerate doctor I have ever met; another says he created a place of love in the burn unit.

The only burn expert between Edmonton and Toronto, he makes himself available 24-7 to residents and nurses, even when not officially on call. The standard of care I try to hold myself toand teach my studentsis What would you expect for you or your loved one? says the father of two kids (under age seven), and husband to epidemiologist Rae Spiwak [BA(Adv)/00, MSc/04, PhD/17], who also studies mental-health issues in trauma patients. The biggest thing Ive learned is that life can change in an instant.

This summer, Logsetty spoke at Winnipegs inaugural Face Equality Awareness event for people living with facial differences. Its important, he adds, to help people understand that, although the outside of somebody might have changed, the inside is still the samepart of what our team does really well is help burn survivors come to that understanding themselves.

It was Beachs wife who held up the mirror for him the first time, only once hed consulted with a psychologist. He couldnt bring himself to look beyond his nose, with its missing lobes and exposed bridge. Gone was the dimpled grin of a guy who was always the life of the party.

Now, if kids stare at the grocery store, hell engage with a smile and a wave. Often, they think hes just really olda grandpa, not a father, to his kids, he says. When adults approach, which hes totally fine with, its always the same question: Can I ask what happened?

Beach doesnt have photos of what he used to look like up in his house, only because theyre not picture people. And no longer does he appear as his former self in his dreams.

Im extremely proud of who I am, Beach says.

Hes a motivational speaker who finds fulfillment in trying to create positive change in the workplacewhos spoken to Winnipeg workers about putting safety before money and supervisors demands. But his life isnt without ongoing challenges.

He has nerve damage and reduced mobility in his joints.

(He says he has the equivalent of seven-and-a-half fingers, since doctors had to amputate portions, up until they found blood flow.) And with some stubborn wounds that wont heal, he regularly gets blood infections20 in the last 10 years. Nonetheless, he renovated his basement and next, hell build a fence.

Im extremely proud of who I am. SPENCER BEACH

With burn survivors like Beach, Logsetty notes, The scar doesnt define them. They define themselves.

In a recent Facebook post, he signed off one tough son-of-a Beach.

You want to be the person you used to be, Beach says, but now you have a different body to do it with.

He returnedjust onceto the site where it happened. Where a new house now stands.

I had to see it.

Early in his career Dr. Sarvesh Logsetty saw how each burn unit across the country was labouring in its own bubble. We have some very good burn centres across Canadapeople are doing great work and researchbut we didnt really work together as a burn program in Canada as a community.

When he joined UM in 2007 he established the Advancement of Burn Care Network and made Winnipeg its base. And last year he launched the Canadian Burn Association and annual symposium further connecting the multidisciplinary players in burn care including firefighters and survivors to learn whats working whats not and what to try next.

He says research in burn treatments is grossly underfunded since there are fewer champions for the cause. Were still at the infancy of really understanding wound healing says Logsetty how to improve it how to avoid scars where we can and how we can make them better.

While the frequency of burns has dropped dramatically since the 1960swith greater safety awareness smoke detectors and legislation to safeguard water heaterstrauma as a whole is still the leading cause of death in Canadians 40 and under. It costs the system more money than just about any other health-care problem thats out there, yet we barely hear about traumatic injury says Logsetty who as a general surgeon is also tasked with removing knives from abdomens after weekend violence, or bowels burst in car collisions. In the last week alone hes removed two spleens ruptured in crashes.

What frustrates me from an academic perspective is that trauma doesnt have a home. There is no institute for traumait gets lumped in under muscoskeletal health and arthritis. That means, in terms of resources, were struggling with identification of the importance of trauma and struggling with helping people understand why we do the research we do and how it affects the people that it affects.

Read this article:
UM Today the Magazine | Fall 2019 | After the Fire - UM Today

Read More...

International Conference on Stem Cells and Regenerative Medicine – Hoover Sun

November 5th, 2019 2:45 pm

Join us! To furnish your research and ideas and to examine your interpretation at International Conference on Stem Cells and Regenerative Medicine which is scheduled on November 06 - 07, 2019 at Tokyo, Japan.

Stem Cells 2019 provides you with a unique platform to share your generous thoughts and ideas related to your research and it adds a valuable acknowledgment to your profile.

The conference is based on the theme of Novel Techniques in Stem Cells and Regenerative Medicine. Based on this, we are delighted to have your presence at our conference.

Highlights include: Stem Cells, Regenerative Medicine, Tissue Regeneration, Therapeutic Cloning, and Stem Cell Transplantation which is detailed in Stem cells

To Visit our conference webpage: http://stemcells.pulsusconference.com/

Hope you will join hands with us to encourage Stem Cells research to have a better tomorrow.

We look forward to receiving a favorable consideration from you.

Explore the evidence to make a difference!

Best Regards,

Veronica Carter

Program Manager | Stem Cells 2019

E: stemcellresearch(at)pulsusglobalevents(dot)com

Ph: 44-203-769-1778

See the original post here:
International Conference on Stem Cells and Regenerative Medicine - Hoover Sun

Read More...

The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics – BioSpace

November 5th, 2019 2:45 pm

WASHINGTON, D.C., Nov. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly sector report, offering an in-depth look at cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the third quarter of 2019.

By further curating information provided by ARMs data partner Informa, the quarterly sector report details industry-specific statistics compiled from 959 cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARMs current strategic priorities.

Amanda Micklus, a senior consultant for Pharma Intelligence at Informa, provided an overview of the commercial, clinical, and regulatory environment in the third quarter of 2019. The report also features commentary from founding members of ARM in honor of the organizations 10-year anniversary. Excerpts from panels at ARMs 2019 Meeting on the Mesa included in the report highlight the continued progress and innovation in the sector.

Highlighted findings from the Q3 2019 data report include:

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trials by phase, and significant clinical data events.

The report isavailable online here, with interactive data and downloadable graphics from the reportavailable here. For more information, please visitwww.alliancerm.orgor contact Lyndsey Scull at lscull@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 350 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Lyndsey Scull202 213 7086lscull@alliancerm.org

Read the original:
The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics - BioSpace

Read More...

Delivering the promise of regenerative medicine – PMLiVE

November 5th, 2019 2:45 pm

The question remains unanswered as to whether a peer-to-peer collaborative model will prosper where medtech companies that are in some instances one step ahead of big pharma in terms of drug development are happy to be a third- party provider to big pharma that have the budgets and networks to truly deliver the regenerative medicine revolution.

In a recent document published by the UK government in response to the Regenerative Medicine Inquiry by the House of Commons Science and Technology Committee, policymakers stressed the importance of commercialising new therapies to meet the changing needs of the health sector.

In the UK, the Regenerative Medicine Expert Group (RMEG) has been tasked with developing an NHS regenerative medicine strategy to ensure the NHS is fully prepared to deliver innovative treatment and that regulations support and not hinder its delivery.

The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between translational research and commercialisation.

However, for the UK to be well-positioned to offer safe and effective regenerative therapies, a strategy is needed that covers the whole value chain from academic research, commercial development and clinical application.

The effect of Brexit on the UKs regenerative medicine sector remains unclear, but the UK has the opportunity to develop an independent framework outside the EU regulatory system to accelerate the development of new therapies and its economic potential while upholding the highest patient safety standards.

In any case, EU and UK regulators need to prioritise the standardisation of regulations governing manufacturing, quality control and the supply chain to keep up with advancements made by the FDA in the US.

Establishing an efficient supply chain for regenerative medicine

The promise of regenerative medicine requires an innovative look at the complete product life cycle, including the development of an efficient distribution network.

Once these novel drugs become mainstream, the entire healthcare ecosystem will have to adapt. Regulatory approval for any drug relies on it safely and successfully fulfilling its medical intent.

As such, information about supply chain management needs to be submitted to the regulator after the completion of phase 3 clinical trials, including packaging, labelling, storage and distribution.

The clinical supply chains required to deliver these therapies are arguably the most complex the industry has seen so far. Regenerative medicine is either personalised or matched to the donor-recipient. They are also highly sensitive to exogenous factors like time and temperature.

Advanced IT solutions and monitoring systems are being developed and employed to ensure end-to-end traceability. These are giving clinicians access to view the progress of therapies and their distribution in real-time and allow users to automatically schedule or amend material collections in line with manufacturing capacity, helping to keep the supply chain as agile as possible.

The live tissues and cells which form the basis of regenerative medicine products are highly sensitive and some have a shelf life of no more than a few hours.

Therefore, materials need to be transported from the site of harvest to manufacturing facilities, and from manufacturing facilities to medical institutions under strictly controlled conditions, within certain times and temperatures, according to cell and tissue requirements.

Temperature-controlled logistics solutions are vital to ensure a safe, effective and financially viable supply chain network for these high-value shipments. Cryopreservation is one technique increasingly being used to deliver medicines at optimum temperature using vapour phase nitrogen; however, many clinical settings remain ill-equipped to handle such equipment.

On-site production is an alternative manufacturing arrangement, particularly for autologous products which are derived from a patients own cells.

However, this throws up a number of compliance and infrastructure challenges, as the hospital would need to comply with a host of regulations including installing a Good Manufacturing Practice (GMP)-licensed clean room.

As a first-generation technology, stakeholders will have a greater tolerance for higher pricing... but only for a limited time period. By streamlining the currently very expensive manufacturing process and improving supply chain management, yields will automatically get larger and costs will slowly come down.

While there are many challenges in the road ahead, 2019 certainly appears to be the start of regenerative medicines move to the big time.

Read more:
Delivering the promise of regenerative medicine - PMLiVE

Read More...

Regenerative Medicine Market Risk Factors, Growth Analysis, Market Size and Innovations By 2028 – 5Gigs News

November 5th, 2019 2:45 pm

New York City, NY: November 05, 2019 The recent update in WorldwideRegenerative Medicine Market begins with description of the merchandise, definition, classification specifications and scope of product Regenerative Medicine market outlook. The Regenerative Medicine report provides forecast amount from 2019 to 2028. It also includes a radical analysis of worldwide market static knowledge, growth factors and geographical region-wise analysis, the highest manufacturers/major players.

It analyse historical Regenerative Medicine market values to figure on latest market wants and estimate future market propensity. It compose of development plans and policies of every and key players at the side of their producing processes and distinct approaches used throughout the method.

The report systematically specialize in competitive analysis of Regenerative Medicine market that disclose prime competitors concerned in marketing and marketing of market merchandise. This research report can provide associate degree detailed and complete info to the readers of Regenerative Medicine market. It conjointly serves a actual analysis of parent market of business with the assistance of past, gift and future market info.

To access the sample report, click here:https://marketresearch.biz/report/regenerative-medicine-market/request-sample

which can be helpful to require decisive judgement of business on Regenerative Medicine market and increase the ratio. the primary five-year accumulative revenue (20192023) of Regenerative Medicine market is projected to be US$ XX Mn, and latter 5 years (20242028) revenue is projected to be US$ XX Mn is calcualted during this report.

Vital Regions that operate Regenerative Medicine market covers geographic region (colombia, Argentina and Brazil), North America (Mexico, North American nation and also the United States), Regenerative Medicine market in Asia-Pacific (China, Japan, Korea, Republic of India and South-East Asia), (UK, Russia, FRG and Italy), the center East and continent (South Africa, UAE, Egypt and Saudi Arabia). Besides, production worth and volume, Regenerative Medicine market share, Regenerative Medicine value, import/export particularisation,SWOT analysis,Regenerative Medicine market growth analysis and price/cost.

Global Regenerative Medicine Market 2019 covers following leading manufacturers:

Organogenesis Inc, Osiris Therapeutics Inc, Pfizer Inc, Novartis AG, Vericel Corporation, NuVasive Inc, Cook Biotech Inc, GlaxoSmithKline plc., Boehringer Ingelheim GmbH, Amgen Inc

Key features of Regenerative Medicine market:

Elaborated data of Regenerative Medicine market opportunities, growth, prohibiting and risk study.

Moreover an entire analysis of existing and rising markets Regenerative Medicine market segments.

Leading market Regenerative Medicine players are present within the report.

The advance market tendencies, startegies and technologies have accelerated range of enterprise models and firms across the world.

Correct arrangement of Regenerative Medicine market is completed on the premise of segments, market size and share.

The information serves during this analysis report isnt solely descriptive in terms of amount however additionally quality.

Every and each Regenerative Medicine data collect from secondary sources are cross examined many times throughout paid primary interviews and business skilled expertize.

Enquire about our Regenerative Medicine report with our industry specialist:https://marketresearch.biz/report/regenerative-medicine-market/#inquiry

The research methodology used to obtained crucial information for Regenerative Medicine market:

1. The analysis methodology of Regenerative Medicine market includes not solely primary however additionally secondary research info sources. It perform distict factors moving business like market setting, varied government policies, historical information and latest trends, technological advancement,market restrains, market risk factors, future innovations,challenges, opportunities and any technical evolution in business.

2. Analysis analysts at first collect the data from distict trivial Regenerative Medicine info sources like monetary reports of the corporate, internet, magazines and analysis reports.

3. The fetched Regenerative Medicine market information is verified and even to assure its quality. varied quality testing techniques are accustomed guarantee its quality of Regenerative Medicine market. theyre approved by attending, conducting and direct interviews and questionnaires with Regenerative Medicine companys business executive, market main opinion leaders, market specialists and business executives.

4. At the end, the info is drawn in pictorial method within the type of tables, bar graphs, pie-charts and figures format. totally different methods are accustomed collect information concerning Regenerative Medicine market size covers high down and bottom-up approach.

5. Resulting a part of the Regenerative Medicine report provides a listing of manufacturers/distributors, information sources, analysis findings, and postscript.

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at[emailprotected].

More here:
Regenerative Medicine Market Risk Factors, Growth Analysis, Market Size and Innovations By 2028 - 5Gigs News

Read More...

RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -…

November 5th, 2019 2:45 pm

HAIFA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the RESTORE Consortium is hosting its 1st Advanced Therapies Science Meeting (ATSM), which is being held November 25-26, 2019 in Berlin. As a leading member of the large-scale research initiative, Pluristem, along with additional respected members, is committed to accelerating the availability of advanced therapies to all those in need, a main motivation standing behind RESTORE.

Led by Charit-Universittsmedizin Berlin, and coordinated by Professor Hans-Dieter Volk from the BIH-Center for Regenerative Therapies in Berlin, RESTORE aims to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need. Advanced Therapies are a potential game changer in health care, aiming to shift our focus from chronic treatment of disease to regeneration of health, said Prof. Volk. We are determined to translate promising research findings into safe therapies, and we are working across disciplines and national borders in order to achieve this goal. The 1st Advanced Therapies Science Meeting provides the opportunity to discuss the still numerous obstacles in the way of implementing these promising therapies in routine clinical care.

This initiative may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, said Zami Aberman, Executive Chairman of Pluristem. The European Commission is poised to make a significant investment of up to 1 billion in a consortium of companies that can drive forward the development of novel regenerative therapies, and we are pleased to be a leading part in this effort. Given our proprietary cell manufacturing technology and broad, late-stage pipeline, we believe we can play a key role toward making the transforming promise of advanced therapies into a reality.

The 1st ATSM will bring together experts from industry, patient organizations and academia to discuss the challenges within the field of advanced therapies, which include gene and cell therapies and tissue-engineering approaches. The ATSM is focused on trying to drive forward a concerted interdisciplinary effort, making use of science, infrastructure and funding within Europe to make regenerative therapies available to the broadest possible patient population.

The two-day program will include talks from Nobel Prize winner Ada Yonath (Director of Weizmann Institute of Science, Israel), Michele De Luca (University of Modena, Italy), Timothy OBrien (National University of Ireland, Galway, Ireland), Maksim Mamonkin (Baylor College of Medicine, USA), Manuela Gomes (University of Minho, Portugal) and others.

RESTORE partners include the Charit Universittsmedizin Berlin and Berlin Institute of Health (Germany), the University of Zurich (Switzerland), Cell and Gene Therapy Catapult (United Kingdom), TissUse GmbH (Germany), Pluristem (Israel), Miltenyi Biotec GmbH (Germany), INSERM Institut National de la Sant et de la Recherche (France), Innovation Acta S.r.l. (Italy), Fondazione Telethon Milan (Italy), and the University of Minho (Portugal).

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor StatementThis press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the potential for the RESTORE Consortium to receive up to a 1 billion award by the European Commission and the timing of the potential award, that RESTOREs aim is to promote groundbreaking research, drive Europe to the forefront in advanced therapies and deliver a pipeline of potentially transformative cures to patients in need, that RESTORE and the 1st ATSM may hold the key for changing the approach towards medicine in Europe, and advancing solutions for patients in need, and its belief that given its proprietary cell manufacturing technology and broad, late-stage pipeline, it believes it can play a key role toward making the transforming promise of advanced therapies into a reality. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

View post:
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare -...

Read More...

2019 Health and Regenerative Medicine Hackathon – University of Victoria News

November 5th, 2019 2:45 pm

Posted By MyUVicLife on Oct 30, 2019 in Hands-on learning, Student life

On the weekend of October 4th, our team participated in this years Health and Regenerative Medicine Hackathon. We thought we would give a quick recap of the event as well as share our experience with you.

By: Natalie Koehn, Jacqui Moreland, Kim Arklie and Jacky Le

The second annual Health and Regenerative Medicine Hackathon was held at FortTectoriain downtown Victoria during the first weekend of October.

Traditionally, a hackathon is a competition where people gather to tackle coding and programming related challenges in a consecutive period of 24-48 hours. However, the Health and Regenerative Medicine Hackathon is different! The challenges as its name suggests are related to health and medicine. Due to the nature of the challenges, competitors were allowed to work on their designs during the month leading up to the Hackathon weekend.

The following challenges were presented to us by various organizations involved in Victorias health industry:

As a combined team of biomedical and mechanical engineers from the University of Victoria, we are passionate about creating assistive technology to solve health-related problems. We had worked together in a school group project in the past and were looking to find another opportunity to work together and design something meaningful.

Inspired by their patient stories and their mission to provide low-cost healthcare opportunities to developing countries, we were eager to take on the Victoria Hand Projects (VHP) challenge to create an assistive device to allow children to write.

A 3D printed solution was optimal for both the rapid prototyping of the Hackathon but also was one of the design requirements for the given project.

In the two weeks leading up to the Hackathon, we came up with a general design concept consisting of two major components an attachment mechanism to the prosthetic hand and a clamping mechanism for the writing utensil. A few iterations were made as a result of tests performed on our original design.

This led us to our final product that utilizes a three-prong and elastic mechanism to grasp the pencil. The pencil is housed in a cylindrical tube, held in place at an optimal angle, that attaches to a simple support that wraps around the bottom of the hand. The hand rests on a bed of silicone at the base of the device in order to prevent unwanted movement, and tightly secured with avelcrostrap.

It was inspiring coming together on the final day of the Hackathon to see the hard work of each group come to life to create such a wide range of solutions. The panel of judges, sponsors and professionals that attended the event were just as passionate about the projects as we were. They provided feedback and support to the teams throughout the Hackathon and helped make the event possible.

All in all, it was a great opportunity and we are looking forward to participating in next years Hackathon. We encourage anyone who is interested in STEM related fields to engage in opportunities like this and explore the design world in a fun, out of school environment!

The views expressed in this blog are my own, and do not necessarily reflect the policies or views of the University of Victoria. I monitor posts and comments to ensure all content complies with the University of Victoria Guidelines on Blogging.

More:
2019 Health and Regenerative Medicine Hackathon - University of Victoria News

Read More...

Intrexon to Announce Third Quarter Financial Results on November 12th – Herald-Mail Media

November 5th, 2019 2:45 pm

GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- Intrexon Corporation(NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release third quarter financial results before the market opens on Tuesday, November 12th, 2019. Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients and a wholly owned subsidiary of Intrexon, will host a conference call that day at 11:00 AM ET to provide Precigen business and pipeline updates.

The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1412-317-6061(International) and providing the number 4454504 to join the Precigen Business and Pipeline Update Call. Participants may also access the live webcast through Intrexon's website in the Investors section at http://investors.dna.com/eventsor Precigen's website in the Presentations section at https://precigen.com/media/#id-presentations.

About Intrexon Corporation Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more at http://www.dna.comor follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.

About Precigen : Advancing Medicine with Precision Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen also follows the science opportunistically in pursuit of promising programs in emerging therapeutics. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. Precigen was founded as a wholly owned subsidiary of Intrexon Corporation(NASDAQ: XON) and leverages a diverse portfolio of technology platforms to advance human health. For more information about Precigen, visit http://www.precigen.comor follow us on Twitter @Precigenand LinkedIn.

Trademarks Intrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Intrexon Investor Contact:

Steven Harasym

Vice President, Investor Relations

Tel: +1 (301) 556-9850

investors@dna.com

Intrexon Corporate Contact:

Marie Rossi, PhD

Vice President, Communications

Tel: +1 (301) 556-9850

publicrelations@dna.com

Precigen Media Contact:

Donelle M. Gregory

press@precigen.com

Continued here:
Intrexon to Announce Third Quarter Financial Results on November 12th - Herald-Mail Media

Read More...

Cancer Gene Therapy Market Value to Hit $2.5 Billion by 2025: Global Market Insights, Inc. – PRNewswire

November 5th, 2019 2:45 pm

SELBYVILLE, Del., Nov. 5, 2019 /PRNewswire/ -- The global Cancer Gene therapy market'srevenue is expected to surpass USD $2.5 billion by 2025, according to a new research report by Global Market Insights, Inc. Rising government initiatives in emerging economies for promoting developments in gene therapies will positively impact the cancer regenerative medicine market's growth. The government often implements several laws and initiatives to motivate scientists and researchers to perform extensive analysesof gene therapies. Furthermore, the government also funds various studies that are carried out for developing molecular therapies utilized in the treatment of cancer. The aforementioned factors should escalate the industry's growth.

There have been several advancements in the biotechnology sector that have proven beneficial for the industry's growth. Several viral vectors have been introduced in the market that work efficiently for carrying out gene transfers. Researchers vigorously work on studying the efficacy and efficiency of the viral, as well as non-viral, vectors that are utilized in gene therapy. Newly developed viral vectors are capable of inhibiting the growth of tumor-inducing genes and are preferred by biopharmaceutical companies. Moreover, healthcare professionals working on gene therapy have started trusting and preferring these viral vectors for treating cancer patients. Therefore, growing advancements will ensure the availability of superior quality vectors for gene transfer, which will foster the market's growth.

Request for a sample of this research report athttps://www.gminsights.com/request-sample/detail/763

The types in the cancer gene market are categorized into in-vivo and ex-vivo. The in-vivo segment of the cancer gene therapy market was valued over USD $350 million in 2018 and will experience substantial growth throughout the analysis period. In-vivo gene therapy is a cost-effective option since it avoids the tedious process of removing cells from a patient's body. Furthermore, in-vivo cancer gene therapy is widely expected to treatcystic fibrosis, which positively influences business growth. However, in recent times, several high-profile, adverse events pertaining to gene therapies were recorded that has reduced its demand, therebylowering the pace of segmental growth.

Based on product, the global market is bifurcated into viral vectors and non-viral vectors. The viral vectors segment of cancer gene therapy is anticipated to foresee around 23% growth throughout the analysis timeframe. Adenovirus is one of the highly preferred viral vectors that has commendable transductional efficiency that raises its adoption. Moreover, theadenovirus vector reduces the risk of mutagenesis. Besides, other viral vectors are also efficient and enable long-term DNA expression, reducing the mortality rate in patients suffering from cancer. The aforementioned factors will spur the viral vectors' segment growth.

Cancer Gene Therapy Market Growth, By Product

5.1. Key segment trends

5.2. Viral vectors5.2.1. Market size, by region, 2014 2025 (USD Million)5.2.2. Adenoviruses5.2.2.1. Market size, by region, 2014 2025 (USD Million)5.2.3. Lentiviruses5.2.3.1. Market size, by region, 2014 2025 (USD Million)5.2.4. Retrovirus5.2.4.1. Market size, by region, 2014 2025 (USD Million)5.2.5. Adeno associated virus5.2.5.1. Market size, by region, 2014 2025 (USD Million)5.2.6. Herpes simplex virus5.2.6.1. Market size, by region, 2014 2025 (USD Million)5.2.7. Vaccinia virus5.2.7.1. Market size, by region, 2014 2025 (USD Million)5.2.8. Others5.2.8.1. Market size, by region, 2014 2025 (USD Million)

5.3. Non-viral vectors5.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Others5.4.1. Market size, by region, 2014 2025 (USD Million)

Browse key industry insights spread across 95 pages, with 120 market data tables and eight figures and charts from the report,Cancer Gene Therapy Market Size By Type (Ex-vivo, In-vivo), By Product (Viral Vectors {Adenoviruses, Lentiviruses, Retrovirus, Adeno Associated Virus, Herpes Simplex Virus, Vaccinia Virus}, Non-viral Vectors), By End-use (Biopharma Companies, Research Institutes), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China), Price Trends, Application Potential, Competitive Market Share & Forecast, 2019 2025," in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/cancer-gene-therapy-market

The end-use segment of cancer gene therapy includes biopharmaceutical companies, research institutes and others. The research institutes segment held around a 40% revenue share in 2018. Significant segmental growth can be attributed to the increasing demand for viral vectors by research institutes that work on cancer gene therapies. Research institutes constantly focus on assessing the efficacy of gene therapies by using different vectors. Moreover, vector manufacturing companies develop superior quality viral, as well as non-viral, vectors that will positively influence the segmental growth.

The U.K. market accounted for around USD $35 million in 2018 and is projected to witness momentous growth during the analysis timeframe. The increasing adoption of cancer gene therapy due to considerably high purchasing power has augmented the cancer gene therapy market growth in the country. Furthermore, the increasing prevalence of cancer has positively influenced the industry's growth. According to a study, in 2017, around 164,901 people died from cancer in the U.K., which creates demand for advanced gene therapies for treating cancer.

Make an inquiry for purchasing this report athttps://www.gminsights.com/inquiry-before-buying/763

Browse Related Reports:

Cancer Diagnostics Market Statistics 2025: Breast cancer is one of the most frequent cancers among womenacross the globe. According to the World Health Organization (WHO), about 2.1 million women are suffering from breast cancer each year. Also, breast cancer rates are higher among women in more developed countries than in developing and under-developed economies. A few prominent players operating in the global market are Abbott, Roche, Siemens Healthcare, Danaher Corporation, Becton, GE Healthcare, Dickinson and Company (BD), Janssen Diagnostics among others.

https://www.gminsights.com/industry-analysis/cancer-diagnostics-market

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun HegdeCorporate Sales, USAGlobal Market Insights, Inc.Phone:1-302-846-7766Toll Free:1-888-689-0688Email:sales@gminsights.com

Related Images

cancer-gene-therapy-market.jpg Cancer Gene Therapy Market Forecasts 2025 Cancer Gene Therapy Market is set to register over a 22% CAGR up to 2025, driven by the rising prevalence of cancer in developed, as well as developing, economies.

Related Links

Cancer Gene Therapy Market size

Cervical Cancer Diagnostic Market

SOURCE Global Market Insights, Inc.

https://www.gminsights.com

View post:
Cancer Gene Therapy Market Value to Hit $2.5 Billion by 2025: Global Market Insights, Inc. - PRNewswire

Read More...

Notch Therapeutics a new company with a revolutionary allogeneic ("off the shelf") T cell technology – GlobeNewswire

November 5th, 2019 2:45 pm

Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships.

The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and CCRM, with Lumira Ventures as an additional investor - created Notch to provide a vehicle through which to further develop and bring to market the combined pioneering research, nearly ten years underway, from the labs of Drs. Juan CarlosZiga-Pflcker,Senior Scientistin Biological Sciences atSunnybrook,and Chair of the Department of Immunology atUoT;andof Peter Zandstra,Professor, Institute of Biomaterials and Biomedical Engineering at UoTandDirector, School of Biomedical engineering and Michael Smith Laboratories at the University of British Columbia.

"This technology is very promising and might be used to create therapiesto treatsome of our greatest medical challenges,like cancer, autoimmune diseases and organ transplant rejection. Its also the first and only method that can reconstitute immune systems," says Dr. Andy Smith, President and CEO of Sunnybrook Health Sciences Centre. "Finally having optionstotarget these high-impact areasfor our patientsis what we mean when we say we are inventing the future of health care."

Jennifer Fraser, Director Innovations at the University of Toronto, comments that "Dr. Ziga-Pflckers allogeneic T cell therapy was one of the first projects I worked on when I joined UoT. Its very gratifying to see the technology move toward the clinic."

Even as the field for these therapies grows rapidly, major challenges have until now prevented wider adoption mainly due to a slow and expensive manufacturing process which yielded variable results. The Notch technology, however, shows promise for surmounting these issues cost-effectively and reliably. Notch, having been incubated at CCRM, will be able to leverage its in-house process development expertise and Good Manufacturing Practices (GMP) facility, located in downtown Toronto. It offersuniversally enhanced T cell therapies against high-impact diseases, using stem cells as a renewable source to expand treatment options and deliver cost-effective immunotherapies to patients. The aim of Notch is to generate T cells from multiple sources of stem cells and provide a platform for research and development, and a better way of manufacturing T cells and their applications for treating cancers or immune deficiencies.

"TIAP is pleased that, after many years of nurturing this research and investing in the risky early-stages with our co-founders, we are now seeing a truly ground-breaking new health science technology make its way through development in a very encouraging way. This is yet another example of what can be done through TIAPs unique ability within the community to bundle technologies across multiple institutions. This is a true collaboration which has resulted in development of a technology that will have significant impact", says Dr. Rafi Hofstein, President & CEO of TIAP.

"Notch Therapeutics is a star pupil in CCRMs incubation program," says Dr. Michael May, President and CEO of CCRM. "By de-risking the technology and designing Proof of Concept studies to appeal to investors, attracting experienced start-up management, and working with our ecosystem partners, we have collectively given Notch every opportunity to succeed."

Dr. Benjamin Rovinski, Managing Director of Lumira Ventures, states: "Early on, our team recognizedNotchs novel and differentiated platform and its potential to produce safer, more effective, and scalable allogeneic T cell therapies. We are pleased to be part of the financing syndicate. The quality and breadth of science coming out of Canadian universities is phenomenal, and important innovators like Notch are able to access capital, knowledge and the engaged support of Lumira and other investors, to enable the development and commercialization of their technology. We are excited to work with the entire Notch team."

About TIAP

TIAP is a leading provider of venture building services, early-stage funding, and deal-brokering with industry and private investors. As a member-based organization made up of 14 member institutions including University of Toronto and affiliated teaching hospitals TIAPs mandate is to drive the commercialization of their most promising research breakthroughs. TIAP has an active portfolio of more than 60 companies in sectors such as therapeutics, medical devices and IT/AI, which have raised in excess of CDN$300M from global investors, and has created more than 1000 direct/indirect jobs.

For more information, please visit http://www.tiap.ca

About University of TorontoFounded in 1827, the University of Toronto is Canadas leading institution of learning, discovery and knowledge creation. U of T is one of the worlds top research-intensive universities, driven to invent and innovate. It is also one of the top five universities in the world for its start-up incubator programs. In the last 10 years, the U of T entrepreneurship community has created over 500 companies and raised over $1.5 billion in investment capital. http://www.utoronto.ca

About Sunnybrook Health Sciences CentreSunnybrook Health Sciences Centre is inventing the future of health care for the 1.3 million patients the hospital cares for each year through the dedication of its more than 10,000 staff and volunteers. An internationally recognized leader in research and education and a full affiliation with the University of Toronto distinguishes Sunnybrook as one of Canadas premier academic health sciences centres. Sunnybrook specializes in caring for high-risk pregnancies, critically-ill newborns and adults, offering specialized rehabilitation and treating and preventing cancer, cardiovascular disease, neurological and psychiatric disorders, orthopaedic and arthritic conditions and traumatic injuries. The Hospital also has a unique and national leading program for the care of Canadas war veterans. For more information about how Sunnybrook is inventing the future of health care. Please visit us online at http://www.sunnybrook.ca

About CCRMCCRM, a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Torontos Medicine by Design. CCRM is hosted by the University of Toronto. Visit us atccrm.ca.

About Lumira VenturesLumira Ventures isCanadasleading and most active healthcare venture capital firm. Lumira invests in best-in-class North American companies developing innovative therapeutics and medical technologies whose products offer transformative improvements to patient health outcomes and provide meaningful reductions to the overall cost of healthcare delivery. Since inception, Lumiras portfolio companies have brought 50+ new therapies to market, impacting the lives of 1+ billion patients globally, generating $65+ billion in cumulative revenue.

For more information, please visit http://www.lumiraventures.com

See the rest here:
Notch Therapeutics a new company with a revolutionary allogeneic ("off the shelf") T cell technology - GlobeNewswire

Read More...

The Bold and the Beautiful Star Don Diamont Supports ALS Research – Soap Hub

November 5th, 2019 2:45 pm

As a member of the daytime community for many years, Don Diamont has seen soaps tackle important social issues. Now, the star of The Bold and the Beautiful is lending his name to a topical and vital concern.

The actor was invited recently to speak at the annual ISSCR (International Society for Stem Cell Research Conference) in Los Angeles. He accepted to show his support for a dear pal, who is battling ALS.

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference, Diamont posted on his Instagram account. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS.

Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI, Diamont continued. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in any way to fight the good fight in eliminating this horrible illness, thank you!

Diamont concluded his post with words of encouragement for his friend: Nanci, you are the bravest of the brave! I, and we LOVE YOU

Soap fans may recall that the late Michael Zaslow (ex-Roger, Guiding Light; ex-David, One Life to Live) had been diagnosed with the disease. He passed away in 1998. For more information on ALS, click here. The Bold and the Beautiful airs weekdays on CBS. Check local listings for air times.

View this post on Instagram

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS. Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in anyway to fight the good fight in eliminating this horrible illness, thank you! Nanci, you are the bravest of the brave! I, and we LOVE YOU

A post shared by Don Diamont (@dondiamont) on Nov 4, 2019 at 4:15pm PST

03:31

Dollar Bill Tribute

Video Credit: SunRiseIta

See original here:
The Bold and the Beautiful Star Don Diamont Supports ALS Research - Soap Hub

Read More...

Lonza Partners with Cryoport and Strengthens its ‘Vein-to-vein’ Delivery Network in Cell & Gene Therapy – Yahoo Finance

November 5th, 2019 2:45 pm

- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis

- Partnership incorporates Cryoport's Cryoportal Logistics Management Platform, SmartPak II Condition Monitoring System and Cryoport's unique Chain of Compliance for regulatory solutions.

- Partnership builds on the recently announced partnership between Lonza and Vineti with an aim to provide cell and gene therapy developers with a fully integrated delivery solutions including manufacturing, supply chain orchestration and logistics, globally

BASEL, Switzerland and IRVINE, Calif., Nov. 5, 2019 /PRNewswire/ --

Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:"The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients. There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency."

Quote from Jerrell Shelton, CEO, Cryoport:"Clinical trial activity in the cell and gene therapy sector is rapidly growing as biopharmaceutical companies discover new ways to harness regenerative therapies and combat illnesses. As more and more of these therapies approach commercialization, there is strengthening demand for reliable, integrated outsourced manufacturing and distribution solutions. Our partnership agreement with Lonza, an internationally-renowned supplier to the pharma and biotech markets, will improve effectiveness, efficiency and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza's manufacturing services."

Lonza (LONN.SW) and Cryoport, Inc. (CYRX) ("Cryoport"),announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza's customers and their patients. Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics -- including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines -- as they prepare for the commercial launch of their respective therapies.

Lonza's network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport's logistics andbioservices solutions with Lonza's manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.

The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry, and process optimization that reduces risk, increases transparency and improves certainty.

Story continues

Cryoport's logistics system aims to provide Lonza's clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals. Beyond Cryoport's proprietary Cryoport Express Shippers, this partnership incorporates Cryoport's Cryoportal Logistics Management Platform and SmartPak II Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport's unique Chain of Compliance for regulatory solutions.

About Lonza Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found atwww.lonza.com.

About CryoportCryoport, Inc. (CYRX) is the world'spremier provider of temperature-controlled supply chain solutions for the life sciences industry,serving the Biopharma, Human Reproductive, and Animal Health markets. Our mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences through our advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting team of professionals. Through purpose-built proprietary packaging; information technology; smart, sustainable cold chain logistics; and biostorage/biobanking services, Cryoport helps its customers advance life sciences research, support life-saving advanced therapies and deliver vaccines, protein producing materials, and IVF treatments in over 100 countries around the world. For more information, visit http://www.cryoport.com or follow @cryoport on Twitter atwww.twitter.com/cryoport for live updates.

Additional Information and Disclaimer (Lonza)Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Forward Looking Statements (Cryoport)Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/lonza-partners-with-cryoport-and-strengthens-its-vein-to-vein-delivery-network-in-cell--gene-therapy-300950920.html

Read the original:
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy - Yahoo Finance

Read More...

Is Dextrose Prolotherapy Superior To Corticosteroid Injection In Patie | ORR – Dove Medical Press

November 5th, 2019 2:45 pm

Masume Bayat,1 Seyed Ahmad Raeissadat,2 Maryam Mortazavian Babaki,3 Shahram Rahimi-Dehgolan4

1Physical Medicine and Rehabilitation Department of Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Clinical Development Research Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Physical Medicine and Rehabilitation Department & Research Center, Shohada-E-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Physical Medicine and Rehabilitation Department of Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Correspondence: Maryam Mortazavian BabakiNo. 1989934148, Shohada-e-Tajrish Hospital, Tehran, IranTel +982122731112Fax +982122724210Email maryam_m.babaky@sbmu.ac.ir

Purpose: To compare the efficacy of dextrose prolotherapy versus steroid injection in the treatment of patients with chronic lateral epicondylitis.Methods: Thirty subjects with chronic lateral epicondylitis were randomly assigned into two groups of hypertonic dextrose or methylprednisolone injection. Participants were assessed through Quick DASH and VAS scores, once before injection, and then after 1- and 3-months follow-up. Two patients were excluded due to not completing the follow-up timepoints.Results: In both groups VAS scores revealed significant improvement during the first month follow-up [mean difference (MD) = 1.93.3, versus 1.51.9 for the prolotherapy and steroid groups, respectively]. This declining trajectory continued at the third month visit in the prolotherapy group and MD reached 4.42.9, while it did not change remarkably in the steroid group (MD=1.93.4). In fact, comparing VAS scores between the 1st- and 3rd-month time points did not reveal a significant improvement in the steroid group (p=0.6). Also, the Quick DASH index showed a similar pattern and improved remarkably in both groups during the first visit. However, only the efficacy in the prolotherapy group persisted after 3-month follow-up (MD = 9.521.6, p=0.044). One month after injections no preference between the two interventions was observed (p=0.74 for VAS and 0.14 for Quick DASH score). However, the 3rd-month follow-up revealed a meaningful superiority (p=0.03 for VAS and p=0.01 for Quick DASH score) favoring the prolotherapy method.Conclusion: Both methods were proven to be effective in the short-term treatment of chronic lateral epicondylitis, but dextrose prolotherapy seems to be slightly more efficacious than steroid injection over a longer period.Clinical trial registration: Iranian Registry of Clinical Trials Database: IRCT20170311033000N3.

Keywords: regenerative medicine, tennis elbow, methylprednisolone, prolotherapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to see the original:
Is Dextrose Prolotherapy Superior To Corticosteroid Injection In Patie | ORR - Dove Medical Press

Read More...

Page 827«..1020..826827828829..840850..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick